No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy
Singh S, Kim J, Zhu W, Dulai P, Sandborn W, Jairath V. No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy. Alimentary Pharmacology & Therapeutics 2020, 52: 481-491. PMID: 32573825, PMCID: PMC8015755, DOI: 10.1111/apt.15876.Peer-Reviewed Original ResearchConceptsAnti-metabolite therapyUlcerative colitisCorticosteroid useRisk of UCCox proportional hazards analysisAdministrative claims databaseEmergency department visitsProportional hazards analysisComorbidity burdenTreatment escalationBiologic therapyAbdominal surgeryDepartment visitsClinical benefitClaims databaseResidual confoundingHigh riskPatientsDisease severityMonotherapyTherapyHospitalisationColitisSurgeryMonths